Title:
METHODS OF DETERMINING ACUTE MYELOID LEUKEMIA RESPONSE TO TREATMENT WITH FARNESYLTRANSFERASE INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2012/016021
Kind Code:
A3
Abstract:
The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1 :APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (Rl 15777, ZARNESTRA®) with etoposide. Further, the elderly AML patients identified as being likely responsive to the combination treatment with tipinifarb and etoposide have a complete recovery rate comparable to the best therapy available for younger patients.
Inventors:
VENER TATIANA I (US)
DERECHO CARLO C (US)
PALMA JOHN F (US)
RAPONI MITCH (US)
DERECHO CARLO C (US)
PALMA JOHN F (US)
RAPONI MITCH (US)
Application Number:
PCT/US2011/045693
Publication Date:
May 03, 2012
Filing Date:
July 28, 2011
Export Citation:
Assignee:
VERIDEX LLC (US)
VENER TATIANA I (US)
DERECHO CARLO C (US)
PALMA JOHN F (US)
RAPONI MITCH (US)
VENER TATIANA I (US)
DERECHO CARLO C (US)
PALMA JOHN F (US)
RAPONI MITCH (US)
International Classes:
G01N33/48
Domestic Patent References:
| WO2008112749A1 | 2008-09-18 |
Foreign References:
| US20050003422A1 | 2005-01-06 | |||
| US20090208942A1 | 2009-08-20 | |||
| US5922571A | 1999-07-13 |
Other References:
RAPONI ET AL.: "A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia", BLOOD, vol. 111, 2008, pages 2589 - 2596, XP055004522
Attorney, Agent or Firm:
JOHNSON, Philip, S. et al. (1 Johnson & Johnson PlazaNew Brunswick, NJ, US)
Download PDF:
Previous Patent: AUTOMATIC ABSTRACTED CREATIVE GENERATION FROM A WEB SITE
Next Patent: PACKAGE WITH CLOSURE, APERTURE, AND INSERT
Next Patent: PACKAGE WITH CLOSURE, APERTURE, AND INSERT